Agile Therapeutics is a women's healthcare company. Co.'s primary product candidate, Twirla, is a once-weekly prescription combination hormonal contraceptive patch. It delivers a dose of estrogen that is consistent with commonly prescribed combined hormonal contraceptives. Co.'s pipeline consists of two classes of product candidates: Co.'s potential product pipeline consists of two types of product candidates: a progestin-only contraceptive patch and potential Twirla line extensions. These potential product candidates are designed to address market needs and provide additional non-daily contraceptive options. Including AG200-15 Extended Regimen, AG200-SmP, and AG200-15 ER SmP. The AGRX average annual return since 2014 is shown above.
The Average Annual Return on the AGRX average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AGRX average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AGRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free AGRX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
